A Randomised, Double-Blind, 2-Period Crossover Study to Assess the Effect of Steady-State AZD6140 on the Pharmacokinetics of a Single Oral 500-mg Dose of Tolbutamide, a Substrate of CYP2C9, in Healthy Male and Female Volunteers.
Study identifier:D5130C00051
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-Blind, 2-Period Crossover Study to Assess the Effect of Steady-State AZD6140 on the Pharmacokinetics of a Single Oral 500-mg Dose of Tolbutamide, a Substrate of CYP2C9, in Healthy Male and Female Volunteers.
Medical condition
Acute Coronary Syndrome
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 2007
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
